CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
骨髓微环境在血液系统恶性肿瘤 CAR-T 疗效中的作用
英文原题：The role of bone marrow microenvironment on CAR-T efficacy in haematologic malignancies.
查看英文原题
The role of bone marrow microenvironment on CAR-T efficacy in haematologic malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
近年来CAR-T 成为新型免疫疗法，在B细胞血液恶性肿瘤中疗效显著，尤其靶向CD19的疗法在B细胞急性淋巴细胞白血病和非霍奇金淋巴瘤中取得前所未有的效果。血液肿瘤干细胞更易停留于骨髓生态位，获得抵御免疫攻击的保护。然而，骨髓微环境如何影响CAR-T 抗肿瘤活性及其机制仍需关注。本文综述骨髓微环境对血液恶性肿瘤CAR-T 疗效的作用，并提出增强疗效的相应策略。
展开英文摘要原文
In recent years, chimeric antigen receptor-T (CAR-T) cell therapy has emerged as a novel immunotherapy method. It has shown significant therapeutic efficacy in the treatment of haematological B cell malignancies.
In particular, the CAR-T therapy targeting CD19 has yielded unprecedented efficacy for acute B-lymphocytic leukaemia (B-ALL) and non-Hodgkin's lymphoma (NHL). In haematologic malignancies, tumour stem cells are more prone to stay in the regulatory bone marrow (BM) microenvironment (called niches), which provides a protective environment against immune attack.
However, how the BM microenvironment affects the anti-tumour efficacy of CAR-T cells and its underlying mechanism is worthy of attention. In this review, we discuss the role of the BM microenvironment on the efficacy of CAR-T in haematological malignancies and propose corresponding strategies to enhance the anti-tumour activity of CAR-T therapy.
论文信息
- 作者
- Gao D、Hong F、He A
- 单位
- Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.China
- 文献类型
- 综述
- 期刊
- Scandinavian journal of immunology2023 Aug
- 原文标识
- PubMed 39007933 · DOI 10.1111/sji.13273